 |
|
|
| |
PRECLINICAL CHARACTERISTICS OF ACH-3422: A POTENT URIDINE NUCLEOTIDE PRODRUG FOR INHIBITION OF HEPATITIS C VIRUS NS5B RNA POLYMERASE
|
| |
| |
Reported by Jules Levin
AASLD 2013 Nov 1-4 Wash DC
Wengang Yang, Jason Wiles, Dharaben Patel, Steven Podos, Joanne Fabrycki, Yongsen Zhao, Lingling Jia, Guangwei Yang, Jose Rivera, Michael Elliot, Christopher Marlor, Akihiro Hashimoto, Godwin Pais, Venkat Gadhachanda, Xiangzhu Wang, Dawei Chen, Qiuping Wang, Milind Deshpande, Mingjun Huang, Kathe Stauber and Avinash Phadke
Achillion Press Release Nov 12 2013:
"Over the next few months our priority is to advance our proprietary assets through critical milestones, including the completion of the preclinical work necessary to initiate first-in-human trials with ACH-3422, our uridine-analog nucleotide prodrug, for the potential treatment of chronic HCV," commented Milind S. Deshpande, Ph.D., President and Chief Executive Officer of Achillion. "Furthermore, we intend to engage in regulatory discussions regarding the path forward for sovaprevir, which remains on clinical hold, and in parallel, we plan to initiate early next year a drug-drug interaction study followed by a therapeutic trial to evaluate our differentiated NS5A inhibitor, ACH-3102, in combination with our macrocyclic protease inhibitor, ACH-2684."
|
| |
|
|
|
|
|
